Overview

Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy

Status:
Unknown status
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
To asess the efficacy of Uroxatrol, an alpha blocker in men undergoing prostate brachytherapy to treat prostate cancer, and whether the use of Uroxatrol in advance of the brachytherapy is better or not than starting it on the day of surgery.
Phase:
Phase 3
Details
Lead Sponsor:
New York Prostate Institute
Collaborator:
Sanofi
Treatments:
Alfuzosin